Skip to main content
. 2010 Mar 23;5(3):e9792. doi: 10.1371/journal.pone.0009792

Figure 4. In vivo effect of the selected compound on various immune cells.

Figure 4

(A) Percentage of B220+, MHC class II+, CD4+, CD8+, CD4 and CD8 double negative cell populations in splenocytes from gp96tm transgenic female mice treated with vehicle (n = 9), GPM1 (n = 9), and dexamethasone (n = 7) at 30mg/kg. (B) Percentages of B220+, MHC class II+, CD4+, CD8+, CD4 and CD8 double negative cell populations in lymph nodes from gp96tm transgenic female mice treated with vehicle (n = 9), GPM1 (n = 9), and dexamethasone (n = 7) at 30mg/kg. (C) Percentage of CD4+CD44high (memory T cells), CD4+CD62Llow (effector T cells), and CD4+CD69+ (activated T cells) in splenocytes from gp96tm transgenic female mice treated with vehicle (n = 9), GPM1 (n = 9), and dexamethasone (n = 7) at 30mg/kg. (D) Percentages of CD4+CD44high, CD4+CD62Llow, and CD4+CD69+ lymph node cells in vehicle- (n = 9), GPM1- (n = 9), and dexamethasone- (n = 7) treated mice. Student t-test P values comparing GPM1-treated mice with control are indicated.